培美曲塞
医学
肺癌
突变体
肿瘤科
鞘内
内科学
癌症
癌症研究
化疗
顺铂
生物
外科
基因
生物化学
作者
Liqun Li,Zhe Huang,Yangqian Chen,Hongzhi Ma,Xiaoquan Chen,Huan Yan,Haoyue Qin,Yuda Zhang,Xing Y. Zhang,Wenjuan Jiang,Zhan Wang,Lin Zhang,Fanxu Zeng,Zhiguo Zhou,Xingxiang Pu,Nong Yang,Liang Zeng,Yongchang Zhang
出处
期刊:Heliyon
[Elsevier BV]
日期:2024-12-01
卷期号:10 (24): e40703-e40703
被引量:9
标识
DOI:10.1016/j.heliyon.2024.e40703
摘要
Objective This study assessed the impact of intrathecal pemetrexed (IP) in managing leptomeningeal metastases (LM) in previously treated patients with EGFR -mutant advanced non-small cell lung cancer (NSCLC). Methods We analyzed the clinical and survival outcomes of 50 patients with LM who received 50 mg IP after disease progression with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment between September 2021 and September 2023 at the Hunan Cancer Hospital. Treatment response was evaluated based on improvement in neurological symptoms/signs and Karnofsky Performance Status (KPS) scores. We also evaluated the overall survival (OS), intracranial progression-free survival (I-PFS), and extracranial progression-free survival (E-PFS). Next generation sequencing (NGS) was employed to explore the underlying mechanisms of LM after EGFR-TKIs resistance. Results IP treatment was associated with a 64 % clinical response rate, median I-PFS of 5.3 months (95 % confidence intervals [CI], 1.4–9.2), E-PFS of 8.0 months (95 % CI, 2.2–13.8), and OS of 12.0 months (95 % CI, 9.6–14.4). Compared with non-responders, responders to IP demonstrated significantly prolonged I-PFS (11.2 months vs. 1.0 month; hazard ratio [HR]: 0.15, 95 % CI: 0.06–0.39), E-PFS (11.2 months vs. 3.0 months; HR: 0.24, 95 % CI: 0.10–0.57), and OS (15.5 months vs. 3.8 months; HR: 0.22, 95 % CI: 0.08–0.58) (all P < 0.001). Adverse events(AEs) primarily consisted of myelosuppression (54 %) and hepatic damage (24 %), but were manageable and did not result in any deaths. EGFR mutations were consistent between cerebrospinal fluid (CSF) and primary tumors in 100 % of cases. CSF also exhibited genetic variations such as EGFR mutations/amplifications and alterations in TP53 , CDKN2A , MET , and CDK6 . Conclusion IP represents a potentially viable treatment option for managing LM in patients with EGFR-TKI-resistant EGFR -mutant advanced NSCLC. Clinical responses as measured by the improvement of neurological symptoms/signs and KPS scores were associated with favorable survival outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI